|
US7803931B2
(en)
|
2004-02-12 |
2010-09-28 |
Archemix Corp. |
Aptamer therapeutics useful in the treatment of complement-related disorders
|
|
AR095196A1
(es)
|
2013-03-15 |
2015-09-30 |
Regeneron Pharma |
Medio de cultivo celular libre de suero
|
|
AU2014286996A1
(en)
|
2013-07-12 |
2016-01-07 |
Iveric Bio, Inc. |
Methods for treating or preventing ophthalmological conditions
|
|
DE202014010499U1
(de)
|
2013-12-17 |
2015-10-20 |
Kymab Limited |
Targeting von humaner PCSK9 zur Cholesterinbehandlung
|
|
US9914769B2
(en)
|
2014-07-15 |
2018-03-13 |
Kymab Limited |
Precision medicine for cholesterol treatment
|
|
GB201403775D0
(en)
|
2014-03-04 |
2014-04-16 |
Kymab Ltd |
Antibodies, uses & methods
|
|
ES2800674T3
(es)
*
|
2014-03-21 |
2021-01-04 |
X Body Inc |
Polipéptidos biespecíficos de unión a antígeno
|
|
US9840553B2
(en)
|
2014-06-28 |
2017-12-12 |
Kodiak Sciences Inc. |
Dual PDGF/VEGF antagonists
|
|
SG11201703428SA
(en)
|
2014-11-10 |
2017-05-30 |
Hoffmann La Roche |
Bispecific antibodies and methods of use in ophthalmology
|
|
EP3218402A1
(en)
|
2014-11-10 |
2017-09-20 |
F. Hoffmann-La Roche AG |
Anti-il-1beta antibodies and methods of use
|
|
JP6946184B2
(ja)
*
|
2014-11-10 |
2021-10-06 |
エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ |
抗ｐｄｇｆ−ｂ抗体及び使用法
|
|
CN107001456A
(zh)
|
2014-11-10 |
2017-08-01 |
豪夫迈·罗氏有限公司 |
抗ang2 抗体及使用方法
|
|
US20160144025A1
(en)
*
|
2014-11-25 |
2016-05-26 |
Regeneron Pharmaceuticals, Inc. |
Methods and formulations for treating vascular eye diseases
|
|
EP3253413A2
(en)
*
|
2015-02-06 |
2017-12-13 |
Kadmon Corporation, LLC |
Immunomodulatory agents
|
|
BR112017020948A2
(pt)
|
2015-03-31 |
2018-07-10 |
Ildong Pharm Co., Ltd. |
composição farmacêutica, método para preparar um agente, método para tratar uma doença ocular e uso de uma proteína de fusão
|
|
CN107849126B
(zh)
|
2015-07-29 |
2022-04-08 |
阿勒根公司 |
仅有重链的抗ang-2抗体
|
|
TW202440903A
(zh)
|
2015-08-04 |
2024-10-16 |
美商再生元醫藥公司 |
補充牛磺酸之細胞培養基及用法（一）
|
|
IL286601B2
(en)
|
2015-12-16 |
2023-09-01 |
Regeneron Pharma |
Preparations and methods for making protein microparticles
|
|
EP3397276A4
(en)
|
2015-12-30 |
2019-12-18 |
Kodiak Sciences Inc. |
ANTIBODIES AND CONJUGATES THEREOF
|
|
JP7461741B2
(ja)
|
2016-06-20 |
2024-04-04 |
カイマブ・リミテッド |
抗ｐｄ－ｌ１およびｉｌ－２サイトカイン
|
|
WO2018005904A2
(en)
*
|
2016-07-01 |
2018-01-04 |
Ludwig Institute For Cancer Research Ltd |
Methods and compositions for pdgf-cc inhibition
|
|
MY198401A
(en)
|
2016-08-16 |
2023-08-28 |
Regeneron Pharma |
Methods for Quantitating Individual Antibodies from A Mixture
|
|
WO2018039499A1
(en)
|
2016-08-24 |
2018-03-01 |
Regeneron Pharmaceuticals, Inc. |
Host cell protein modification
|
|
WO2018083248A1
(en)
|
2016-11-03 |
2018-05-11 |
Kymab Limited |
Antibodies, combinations comprising antibodies, biomarkers, uses & methods
|
|
CN109021104B
(zh)
*
|
2017-06-12 |
2022-08-12 |
上海睿智化学研究有限公司 |
一种抗人血小板衍生生长因子β受体的抗体及其应用
|
|
WO2019010191A1
(en)
|
2017-07-06 |
2019-01-10 |
Regeneron Pharmaceuticals, Inc. |
CELL CULTURE METHOD FOR PRODUCING GLYCOPROTEIN
|
|
JP7321159B2
(ja)
|
2017-12-22 |
2023-08-04 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
薬剤生成物不純物を特性決定するためのシステム及び方法
|
|
SG11202005235WA
(en)
|
2018-01-31 |
2020-07-29 |
Regeneron Pharma |
System and method for characterizing size and charge variant drug product impurities
|
|
TW202311746A
(zh)
|
2018-02-02 |
2023-03-16 |
美商再生元醫藥公司 |
用於表徵蛋白質二聚合之系統及方法
|
|
EP3759242A1
(en)
|
2018-02-28 |
2021-01-06 |
Regeneron Pharmaceuticals, Inc. |
Systems and methods for identifying viral contaminants
|
|
US12071476B2
(en)
|
2018-03-02 |
2024-08-27 |
Kodiak Sciences Inc. |
IL-6 antibodies and fusion constructs and conjugates thereof
|
|
TWI854343B
(zh)
|
2018-03-19 |
2024-09-01 |
美商再生元醫藥公司 |
微晶片毛細管電泳分析及試劑
|
|
US12259355B2
(en)
|
2018-03-19 |
2025-03-25 |
Regeneron Pharmaceuticals, Inc. |
Microchip capillary electrophoresis assays and reagents
|
|
US12253490B2
(en)
|
2018-03-19 |
2025-03-18 |
Regeneron Pharmaceuticals, Inc. |
Microchip capillary electrophoresis assays and reagents
|
|
GB201806918D0
(en)
*
|
2018-04-27 |
2018-06-13 |
Enleofen Bio Pte Ltd |
Combination treatment for eye fibrosis
|
|
CN108586611B
(zh)
*
|
2018-04-28 |
2021-01-26 |
暨南大学 |
重组全人源抗破伤风毒素单克隆抗体
|
|
TW202016125A
(zh)
|
2018-05-10 |
2020-05-01 |
美商再生元醫藥公司 |
用於定量及調節蛋白質黏度之系統與方法
|
|
JP2021535739A
(ja)
|
2018-08-27 |
2021-12-23 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
下流精製でのラマン分光法の使用
|
|
CA3100038A1
(en)
|
2018-08-30 |
2020-03-05 |
Regeneron Pharmaceuticals, Inc. |
Methods for characterizing protein complexes
|
|
WO2020071881A1
(ko)
*
|
2018-10-05 |
2020-04-09 |
서울대학교산학협력단 |
Pdgf 수용체에 대한 항체 및 이의 용도
|
|
EA202191841A1
(ru)
|
2019-01-16 |
2021-10-07 |
Ридженерон Фармасьютикалз, Инк. |
Способы для идентификации свободных тиолов в белках
|
|
EP3935084B1
(en)
*
|
2019-03-08 |
2024-06-12 |
LinXis B.V. |
Internalizing binding molecules targeting receptors involved in cell proliferation or cell differentiation
|
|
PH12021552763A1
(en)
|
2019-05-03 |
2022-07-04 |
Nat Univ Singapore |
Treatment and prevention of metabolic diseases
|
|
MX2021013519A
(es)
|
2019-05-13 |
2021-12-10 |
Regeneron Pharma |
Ensayos de union de ligandos competitivos mejorados.
|
|
CN120334439A
(zh)
|
2019-09-24 |
2025-07-18 |
里珍纳龙药品有限公司 |
用于色谱介质的使用和再生的系统及方法
|
|
AU2020364071A1
(en)
|
2019-10-10 |
2022-05-26 |
Kodiak Sciences Inc. |
Methods of treating an eye disorder
|
|
US12297451B1
(en)
|
2019-10-25 |
2025-05-13 |
Regeneron Pharmaceuticals, Inc. |
Cell culture medium
|
|
CN119318636A
(zh)
|
2019-11-25 |
2025-01-17 |
里珍纳龙药品有限公司 |
使用非水性乳液的持续释放调配物
|
|
EP4087657A1
(en)
|
2020-01-08 |
2022-11-16 |
Synthis Therapeutics, Inc. |
Alk5 inhibitor conjugates and uses thereof
|
|
MX2022008973A
(es)
|
2020-01-21 |
2022-08-11 |
Regeneron Pharma |
Metodos de desglicosilacion para electroforesis de proteinas glicosiladas.
|
|
JP2023513155A
(ja)
*
|
2020-02-07 |
2023-03-30 |
バイオリオン テクノロジーズ ビー．ブイ． |
血小板由来成長因子受容体（ｐｄｇｆｒ）抗体、コンジュゲート、組成物、及びそれらの使用
|
|
BR112023003273A2
(pt)
|
2020-08-31 |
2023-05-02 |
Regeneron Pharma |
Estratégias de alimentação de asparagina para melhorar desempenho da cultura celular e mitigar variantes da sequência de asparagina
|
|
WO2022060223A1
(en)
*
|
2020-09-16 |
2022-03-24 |
Linxis B.V. |
Internalizing binding molecules
|
|
EP4251128A1
(en)
|
2020-11-25 |
2023-10-04 |
Regeneron Pharmaceuticals, Inc. |
Sustained release formulations using non-aqueous membrane emulsification
|
|
CN116710124A
(zh)
|
2020-12-17 |
2023-09-05 |
瑞泽恩制药公司 |
包封蛋白质的微凝胶的制造
|
|
AU2022209730A1
(en)
|
2021-01-20 |
2023-07-13 |
Regeneron Pharmaceuticals, Inc. |
Methods of improving protein titer in cell culture
|
|
AU2022230987A1
(en)
|
2021-03-03 |
2023-08-31 |
Regeneron Pharmaceuticals, Inc. |
Systems and methods for quantifying and modifying protein viscosity
|
|
JP2024519407A
(ja)
|
2021-03-26 |
2024-05-13 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
混合プロトコルを作成するための方法およびシステム
|
|
BR112023024984A2
(pt)
|
2021-06-01 |
2024-02-20 |
Regeneron Pharma |
Tampão de amostra de eletroforese aquosa, método para identificar contaminantes ou impurezas em uma amostra de droga proteica, e, kit
|
|
US20230077710A1
(en)
|
2021-09-08 |
2023-03-16 |
Regeneron Pharmaceuticals, Inc. |
HIGH-THROUGHPUT AND MASS-SPECTROMETRY-BASED METHOD FOR QUANTITATING ANTIBODIES AND OTHER Fc-CONTAINING PROTEINS
|
|
WO2023044139A1
(en)
|
2021-09-20 |
2023-03-23 |
Regeneron Pharmaceuticals, Inc. |
Methods of controlling antibody heterogeneity
|
|
KR20240090312A
(ko)
|
2021-10-07 |
2024-06-21 |
리제너론 파아마슈티컬스, 인크. |
Ph 미터 보정 및 교정
|
|
MX2024004107A
(es)
|
2021-10-07 |
2024-04-19 |
Regeneron Pharma |
Sistemas y metodos para modelar y controlar el ph.
|
|
IL312372A
(en)
|
2021-10-26 |
2024-06-01 |
Regeneron Pharma |
Systems and methods for producing laboratory water and dispersing laboratory water at different temperatures
|
|
CN119137473A
(zh)
|
2022-03-18 |
2024-12-13 |
里珍纳龙药品有限公司 |
分析多肽变体的方法及系统
|
|
US11723955B1
(en)
|
2022-05-13 |
2023-08-15 |
Allgenesis Biotherapeutics Inc. |
VEGFR fusion protein pharmaceutical composition
|
|
TW202435942A
(zh)
|
2022-12-16 |
2024-09-16 |
美商里珍納龍藥品有限公司 |
評估層析管柱完整性的方法及系統
|
|
TW202445135A
(zh)
|
2023-01-25 |
2024-11-16 |
美商再生元醫藥公司 |
液態蛋白質組成物穩定性之建模方法
|
|
WO2024158961A1
(en)
|
2023-01-25 |
2024-08-02 |
Regeneron Pharmaceuticals, Inc. |
Mass spectrometry-based characterization of antibodies co-expressed in vivo
|
|
US20240255519A1
(en)
|
2023-02-01 |
2024-08-01 |
Regeneron Pharmaceuticals, Inc. |
Asymmetrical flow field-flow fractionation with mass spectrometry for biomacromolecule analysis
|
|
US20240280551A1
(en)
|
2023-02-22 |
2024-08-22 |
Regeneron Pharmaceuticals, Inc. |
System suitability parameters and column aging
|
|
TW202508625A
(zh)
|
2023-05-01 |
2025-03-01 |
美商再生元醫藥公司 |
使用苯酚或苯甲醇之多劑量抗體藥物產品
|
|
US20250086164A1
(en)
|
2023-09-08 |
2025-03-13 |
Regeneron Pharmaceuticals, Inc. |
Methods and systems for assessing chromatographic column integrity
|
|
WO2025064403A2
(en)
|
2023-09-18 |
2025-03-27 |
Regeneron Pharmaceuticals, Inc. |
Methods and systems for developing chromatography protocols
|
|
US20250109905A1
(en)
|
2023-09-29 |
2025-04-03 |
Regeneron Pharmaceuticals, Inc. |
Lyophilization using controlled nucleation
|
|
WO2025085594A1
(en)
|
2023-10-18 |
2025-04-24 |
Regeneron Pharmaceuticals, Inc. |
Rapid purification of monoclonal antibody from in-process upstream cell culture material
|
|
TW202535934A
(zh)
|
2023-11-02 |
2025-09-16 |
美商再生元醫藥公司 |
利用應力來降低脂酶活性的方法
|
|
WO2025166281A1
(en)
|
2024-02-01 |
2025-08-07 |
Regeneron Pharmaceuticals, Inc. |
Platform for charge-detection mass spectrometry analysis of aavs
|
|
WO2025175164A1
(en)
|
2024-02-16 |
2025-08-21 |
Regeneron Pharmaceuticals, Inc. |
Methods of producing concentrated formulated drug substances comprising proteins, and concentrated formulated drug substance made by the methods
|
|
WO2025194043A1
(en)
|
2024-03-15 |
2025-09-18 |
Regeneron Pharmaceuticals, Inc. |
Polysorbate and polyoxyethylene sorbitan as excipients for stable protein formulations
|
|
CN118440214B
(zh)
*
|
2024-04-02 |
2025-01-28 |
山东大学 |
一种靶向PDGFRβ的嵌合抗原受体、CAR-T细胞及应用
|
|
WO2025259840A1
(en)
|
2024-06-13 |
2025-12-18 |
Regeneron Pharmaceuticals, Inc. |
Methods and systems for scaled chromatography
|